Age, mean (range), years | 63 (35–82) |
---|---|
Sex ratio, m:f | 82:8 (9:1) |
Type of initial neoplasia | |
LGIN | 4 |
HGIN | 32 |
Cancer | 54 |
Mode of therapy, n (%) | |
EMR alone | 38 (42.2) |
EMR plus APC | 48 (53.3) |
EMR plus RFA | 3 (3.3) |
EMR plus APC plus RFA | 1 (1.1) |
Number of sessions, mean (range) | |
EMR | 2.1 (1–7) |
Additional APC (n=48) | 1 (1–4) |
Additional APC+RFA (n=4) | 1 (1–4) |
Duration of primary treatment inclusive of all sessions, mean (range), weeks | 73.4 (38–132) |
Stricture development (requiring dilation), n (%) | 43 (47.8) |
Number of dilations (if applicable), mean (range) | 3.3 (1–31) |
Duration of dilation therapy, mean (range), weeks | 7.9 (1–46) |
Follow-up after completed therapy* | |
Duration, mean (range), months | 64.8 (36–129) |
Number of endoscopies with biopsies, mean (range) | 6.4 (1†–15) |
Of all 179 cases included in the analysis (intention to treat, data see text) 90 patients formed the subgroup in whom complete Barrett's ablation was intended and follow-up information available (see figure 1).
*Follow-up time was counted after either termination of ablation (EMR, APC) or, if needed, additional dilation therapy.
†The patient with only one follow-up had a normal endoscopy with normal biopsies 85 months after completion of endotherapy.
APC, argon plasma coagulation; EMR, endoscopic mucosal resection; HGIN, high-grade intraepithelial neoplasia; LGIN, low-grade intraepithelial neoplasia; RFA, radiofrequency ablation.